Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases
Crossref DOI link: https://doi.org/10.1007/s00228-017-2362-8
Published Online: 2017-11-10
Published Print: 2018-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Albach, Fredrik N.
Wagner, Frank
Hüser, Andreas
Igel, Julia
Joseph, David
Hilbert, James
Schoelch, Corinna
Padula, Steven J.
Steffgen, Jürgen
Funding for this research was provided by:
Boehringer Ingelheim
License valid from 2017-11-10